These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7800165)

  • 1. Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects.
    Monteleone P; Piccolo A; Martino M; Maj M
    Neuropsychobiology; 1994; 30(2-3):61-5. PubMed ID: 7800165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seasonal variations of the dexamethasone suppression test in depression compared with schizophrenia: a gender effect.
    Rybakowski J; Plocka M
    J Affect Disord; 1992 Feb; 24(2):87-91. PubMed ID: 1541770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dexamethasone suppression test and negative symptoms of schizophrenia.
    McGauley GA; Aldridge CR; Fahy TA; Eastment C
    Acta Psychiatr Scand; 1989 Dec; 80(6):548-53. PubMed ID: 2618777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome.
    Tandon R; Mazzara C; DeQuardo J; Craig KA; Meador-Woodruff JH; Goldman R; Greden JF
    Biol Psychiatry; 1991 May; 29(10):953-64. PubMed ID: 1676605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms of schizophrenia and the dexamethasone suppression test.
    Garyfallos G; Lavrentiadis G; Amoutzias D; Monas K; Manos N
    Acta Psychiatr Scand; 1993 Dec; 88(6):425-8. PubMed ID: 8310850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
    Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
    Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II.
    Lammers CH; Garcia-Borreguero D; Schmider J; Gotthardt U; Dettling M; Holsboer F; Heuser IJ
    Biol Psychiatry; 1995 Dec; 38(12):803-7. PubMed ID: 8750038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment.
    Wik G; Wiesel FA; Eneroth P; Sedvall G; Aström G
    Acta Psychiatr Scand; 1986 Aug; 74(2):161-7. PubMed ID: 2877544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dexamethasone suppression test in residual schizophrenia with depression.
    Munro JG; Hardiker TM; Leonard DP
    Am J Psychiatry; 1984 Feb; 141(2):250-2. PubMed ID: 6691488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone suppression test, schizophrenia and movement disorder.
    Aleem A; Kulkarni A; Yeragani VK
    Acta Psychiatr Scand; 1988 Dec; 78(6):689-94. PubMed ID: 3223326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone suppression test and depressive symptoms in schizophrenics and endogenous depressed patients.
    Perényi A; Frecska E; Rihmer Z; Arató M
    Pharmacopsychiatry; 1987 Mar; 20(2):48-50. PubMed ID: 3588661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal variation and the results of the dexamethasone suppression test.
    Harris B; Watkins S; Newcombe R; Cook N; Read G; Riad-Fahmy D
    J Affect Disord; 1990 Oct; 20(2):115-20. PubMed ID: 2148325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features.
    Kaneko M; Yokoyama F; Hoshino Y; Takahagi K; Murata S; Watanabe M; Kumashiro H
    Neuropsychobiology; 1992; 25(1):1-7. PubMed ID: 1351264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dexamethasone suppression test in newly hospitalized schizophrenic patients.
    Herz MI; Fava GA; Molnar G; Edwards L
    Am J Psychiatry; 1985 Jan; 142(1):127-9. PubMed ID: 3966575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal dexamethasone suppression test results in chronic schizophrenic patients.
    Dewan MJ; Pandurangi AK; Boucher ML; Levy BF; Major LF
    Am J Psychiatry; 1982 Nov; 139(11):1501-3. PubMed ID: 7137407
    [No Abstract]   [Full Text] [Related]  

  • 17. Nocturnal melatonin and cortisol secretion in newly admitted psychiatric inpatients. Implications for affective disorders.
    Steiner M; Brown GM; Goldman S
    Eur Arch Psychiatry Clin Neurosci; 1990; 240(1):21-7. PubMed ID: 2147898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients.
    Jiang HK; Wang JY
    J Formos Med Assoc; 1998 Dec; 97(12):830-7. PubMed ID: 9884485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between dexamethasone nonsuppression and negative symptoms in schizophrenic patients.
    Tandon R
    Acta Psychiatr Scand; 1989 Nov; 80(5):524-5. PubMed ID: 2574530
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study.
    Venkatasubramanian G; Chittiprol S; Neelakantachar N; Shetty T; Gangadhar BN
    Schizophr Res; 2010 Jun; 119(1-3):131-7. PubMed ID: 20226630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.